Table 1. Patient baseline characteristics.
Characteristic, n (% unless otherwise stated) | DI (n=42)a | DF (n=43)a | Total (n=85) |
---|---|---|---|
Male | 35 (83.3) | 35 (81.4) | 70 (82.4) |
Race | |||
Caucasian | 40 (95.2) | 42 (97.7) | 82 (96.5) |
Other | 2 (4.8) | 1 (2.3) | 3 (3.5) |
Age | |||
<65 years | 26 (61.9) | 31 (72.1) | 57 (67.1) |
⩾65 years | 16 (38.1) | 12 (27.9) | 28 (32.9) |
Median age (range), years | 62 (40–76) | 60 (38–74) | 61 (38–76) |
KPS before first infusion | |||
⩾90 | 24 (57.1) | 20 (46.5) | 44 (51.8) |
100 | 7 (16.7) | 9 (20.9) | 16 (18.8) |
90 | 17 (40.5) | 11 (25.6) | 28 (32.9) |
80 | 12 (28.6) | 11 (25.6) | 23 (27.1) |
70 | 6 (14.3) | 12 (27.9) | 18 (21.2) |
Median KPS (range) score | 90 (70–100) | 80 (70–100) | 90 (70–100) |
Weight loss in prior 3 months | |||
⩽5% | 12 (28.6) | 14 (32.6) | 26 (30.6) |
>5%–⩽10% | 16 (38.1) | 10 (23.3) | 26 (30.6) |
>10% | 14 (33.3) | 19 (44.2) | 33 (38.8) |
Median (range) weight loss in prior 3 months, % | 9 (0–25) | 10 (0–30) | 10 (0–30) |
Primary tumour site | |||
Distal (antrum+body) | 27 (64.3) | 19 (44.2) | 46 (54.1) |
Proximal (oesophagogastric junction, fundus) | 15 (35.7) | 24 (55.8) | 39 (45.9) |
Disease status | |||
Metastatic | 40 (95.2) | 40 (93.0) | 80 (94.1) |
Locally advanced | 2 (4.8) | 3 (7.0) | 5 (5.9) |
Histology | |||
Adenocarcinoma | 40 (95.2) | 40 (93.0) | 80 (94.1) |
Linitis plastica | 2 (4.8) | 3 (7.0) | 5 (5.9) |
Number of organs involved | |||
1 | 8 (19.0) | 12 (27.9) | 20 (23.5) |
2 | 18 (42.9) | 16 (37.2) | 34 (40.0) |
⩾3 | 16 (38.1) | 15 (34.9) | 31 (36.5) |
Prior therapies | |||
Radiotherapy | — | — | — |
Chemotherapy (adjuvant/neoadjuvant) | 2 (4.8) | 1 (2.3) | 3 (3.5) |
Surgery | 16 (38.1) | 15 (34.9) | 31 (36.5) |
Curative intent | 9 (21.4) | 11 (25.6) | 20 (23.5) |
Palliative | 7 (16.7) | 4 (9.3) | 11 (12.9) |
Abbreviations: DF=docetaxel and 5-fluorouracil; DI=docetaxel and irinotecan; ITT=intention-to-treat; KPS=Karnofsky performance status.
ITT population.